Apollomics Net Worth
Apollomics Net Worth Breakdown | APLM |
Apollomics Net Worth Analysis
Apollomics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Apollomics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Apollomics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Apollomics' net worth analysis. One common approach is to calculate Apollomics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Apollomics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Apollomics' net worth. This approach calculates the present value of Apollomics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Apollomics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Apollomics' net worth. This involves comparing Apollomics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Apollomics' net worth relative to its peers.
To determine if Apollomics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Apollomics' net worth research are outlined below:
| Apollomics Class A had very high historical volatility over the last 90 days | |
| Apollomics Class A has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 821 K. Net Loss for the year was (172.59 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Apollomics generates negative cash flow from operations | |
| About 47.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Apollomics Shares Scheduled to Reverse Split on Monday, November 25th |
Apollomics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Apollomics Class A. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Apollomics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Apollomics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 16.52 M.Market Cap |
|
Project Apollomics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (4.25) | (4.46) | |
| Return On Capital Employed | (1.31) | (1.38) | |
| Return On Assets | (3.12) | (3.27) | |
| Return On Equity | (4.19) | (3.98) |
When accessing Apollomics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Apollomics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Apollomics' profitability and make more informed investment decisions.
Evaluate Apollomics' management efficiency
Apollomics Class A has return on total asset (ROA) of (0.6274) % which means that it has lost $0.6274 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4931) %, meaning that it created substantial loss on money invested by shareholders. Apollomics' management efficiency ratios could be used to measure how well Apollomics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of November 2024, Return On Tangible Assets is likely to drop to -4.46. In addition to that, Return On Capital Employed is likely to drop to -1.38. At this time, Apollomics' Fixed Asset Turnover is very stable compared to the past year. As of the 28th of November 2024, Asset Turnover is likely to grow to 0.02, while Return On Tangible Assets are likely to drop (4.46).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.55 | 0.58 | |
| Tangible Book Value Per Share | 0.36 | 0.37 | |
| Enterprise Value Over EBITDA | (41.64) | (43.72) | |
| Price Book Value Ratio | 174.11 | 182.82 | |
| Enterprise Value Multiple | (41.64) | (43.72) | |
| Price Fair Value | 174.11 | 182.82 | |
| Enterprise Value | 6.4 B | 5.7 B |
The decision-making processes within Apollomics are key to its success in a competitive market. By evaluating these processes, we assess the stock's potential for future gains.
Revenue 2.1 M | Quarterly Revenue Growth 2.623 | Revenue Per Share 0.023 | Return On Equity (1.49) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Apollomics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Apollomics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Apollomics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yungfong Song over six months ago Conversion by Yungfong Song of 2482500 shares of Apollomics |
Apollomics Corporate Filings
6K | 14th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
F3 | 15th of August 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 30th of May 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 29th of May 2024 Other Reports | ViewVerify |
Apollomics Earnings per Share Projection vs Actual
Apollomics Corporate Management
| Matthew Plunkett | Chief Officer | Profile | |
| Chinglin Lai | Senior Management | Profile | |
| KinHung MD | Chief Officer | Profile | |
| Lijuan Wang | Chief China | Profile |
Already Invested in Apollomics Class A?
The danger of trading Apollomics Class A is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Apollomics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Apollomics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Apollomics Class A is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Apollomics Class A is a strong investment it is important to analyze Apollomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Apollomics' future performance. For an informed investment choice regarding Apollomics Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apollomics Class A. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.15) | Revenue Per Share 0.023 | Quarterly Revenue Growth 2.623 | Return On Assets (0.63) | Return On Equity (1.49) |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.